Hikma buys Boehringer's injectable drugs business

Hikma Pharmaceuticals (HKMPF) has agreed to buy the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300M, as it attempts to boost its "injected medicine" market share.

The company will pay $225M upfront for the assets of Boehringer's Bedford Laboratories and another $75M over the course of five years based on the performance of the drugs.

This was corrected on 05/28/2014 at 09:11 AM.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs